PTGX
VENTE TOTALE: 225 000 titres (~33 131 366,81 $ US)
- Insiders
- PATEL DINESH V PH D
- Total bought
- —
- Total sold
- $33,131,367
- Last activity
- 2026-09-10
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-11
PTGX has a meaningful catalyst in the FDA approval of MIMRYLO and a $300M buyback, but the event-driven signal is significantly undermined by $33M in insider selling post-approval, suggesting insiders are cashing out…
The first sentence of the analysis written for PTGX on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -281.0% | 64.3% | -131.6% | -479.3% | -458.9% | |
| Ebitda Margin | -278.4% | 64.5% | -126.1% | -466.6% | -448.8% | |
| Operating Profit Margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | |
| Pretax Profit Margin | -281.0% | 64.3% | -131.6% | -479.3% | -458.9% | |
| Continuous Operations Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Net Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Bottom Line Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Current Ratio | 12.710 | 12.482 | 16.714 | 7.796 | 7.741 | |
| Quick Ratio | 12.710 | 12.482 | 16.714 | 7.796 | 7.741 | |
| Solvency Ratio | -2.336 | 3.975 | -3.556 | -3.837 | -2.575 | |
| Cash Ratio | 2.825 | 2.052 | 8.777 | 4.033 | 2.810 | |
| Price To Earnings Ratio | -42.605 | 8.635 | -16.496 | -4.329 | -12.906 | |
| Price To Earnings Growth Ratio | 0.292 | -0.020 | 0.368 | 0.883 | -0.339 | |
| Forward Price To Earnings Growth Ratio | 0.292 | -0.020 | 0.368 | 0.883 | -0.339 | |
| Price To Earnings Diluted Ratio | -42.605 | 9.125 | -16.496 | -4.329 | -12.906 | |
| Price To Earnings Diluted Growth Ratio | 0.287 | -0.023 | 0.368 | 0.883 | -0.339 | |
| Price To Book Ratio | 9.033 | 3.519 | 3.866 | 2.482 | 5.280 | |
| Price To Sales Ratio | 120.664 | 5.470 | 21.693 | 20.129 | 57.910 | |
| Price To Free Cash Flow Ratio | 99.008 | 13.001 | -18.372 | -4.912 | -14.539 | |
| Price To Operating Cash Flow Ratio | 96.278 | 12.905 | -18.532 | -4.948 | -14.687 | |
| Debt To Assets Ratio | 0.015 | 0.015 | 0.003 | 0.015 | 0.017 | |
| Debt To Equity Ratio | 0.017 | 0.016 | 0.003 | 0.017 | 0.020 | |
| Debt To Capital Ratio | 0.017 | 0.016 | 0.003 | 0.017 | 0.019 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.103 | 1.063 | 1.150 | 1.159 | |
| Working Capital Turnover Ratio | 0.086 | 0.989 | 0.220 | 0.105 | 0.096 | |
| Operating Cash Flow Ratio | 1.269 | 3.885 | -3.301 | -3.468 | -2.451 | |
| Operating Cash Flow Sales Ratio | 1.253 | 0.424 | -1.171 | -4.068 | -3.943 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.972 | 0.993 | 1.009 | 1.007 | 1.010 | |
| Debt Service Coverage Ratio | -56.471 | 541.204 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 25.261 | 361.082 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 5.587 | 16.948 | -61.557 | -29.578 | -18.413 | |
| Capital Expenditure Coverage Ratio | 36.271 | 135.906 | -115.330 | -136.021 | -97.970 | |
| Dividend Paid And Capex Coverage Ratio | 36.271 | 135.906 | -115.330 | -136.021 | -97.970 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -42.428 | 8.172 | -14.754 | -3.330 | -11.944 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.3% | ▼-2.7% | ▼-2.1% |
| Ebit Margin | -281.0% | ▼-345.3% | ▼-23.7% |
| Ebitda Margin | -278.4% | ▼-342.9% | ▼-27.3% |
| Operating Profit Margin | -343.6% | ▼-401.8% | ▼-64.5% |
| Pretax Profit Margin | -281.0% | ▼-345.3% | ▼-23.7% |
| Continuous Operations Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Net Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Bottom Line Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Current Ratio | 12.710 | ▲0.228 | ▲1.222 |
| Quick Ratio | 12.710 | ▲0.228 | ▲1.222 |
| Solvency Ratio | -2.336 | ▼-6.312 | ▼-0.670 |
| Cash Ratio | 2.825 | ▲0.774 | ▼-1.274 |
| Price To Earnings Ratio | -42.605 | ▼-51.240 | ▼-29.065 |
| Price To Earnings Growth Ratio | 0.292 | ▲0.313 | ▲0.056 |
| Forward Price To Earnings Growth Ratio | 0.292 | ▲0.313 | ▲0.056 |
| Price To Earnings Diluted Ratio | -42.605 | ▼-51.730 | ▼-29.163 |
| Price To Earnings Diluted Growth Ratio | 0.287 | ▲0.309 | ▲0.052 |
| Price To Book Ratio | 9.033 | ▲5.513 | ▲4.197 |
| Price To Sales Ratio | 120.664 | ▲115.194 | ▲75.491 |
| Price To Free Cash Flow Ratio | 99.008 | ▲86.007 | ▲84.171 |
| Price To Operating Cash Flow Ratio | 96.278 | ▲83.373 | ▲82.075 |
| Debt To Assets Ratio | 0.015 | ▲0.001 | ▲0.003 |
| Debt To Equity Ratio | 0.017 | ▲0.001 | ▲0.002 |
| Debt To Capital Ratio | 0.017 | ▲0.001 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.090 | ▼-0.013 | ▼-0.023 |
| Working Capital Turnover Ratio | 0.086 | ▼-0.903 | ▼-0.213 |
| Operating Cash Flow Ratio | 1.269 | ▼-2.616 | ▲2.082 |
| Operating Cash Flow Sales Ratio | 1.253 | ▲0.829 | ▲2.754 |
| Free Cash Flow Operating Cash Flow Ratio | 0.972 | ▼-0.020 | ▼-0.026 |
| Debt Service Coverage Ratio | -56.471 | ▼-597.675 | ▼-153.418 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 25.261 | ▼-335.821 | ▼-52.008 |
| Operating Cash Flow Coverage Ratio | 5.587 | ▼-11.361 | ▲22.989 |
| Capital Expenditure Coverage Ratio | 36.271 | ▼-99.635 | ▲71.700 |
| Dividend Paid And Capex Coverage Ratio | 36.271 | ▼-99.635 | ▲71.700 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -42.428 | ▼-50.600 | ▼-29.571 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $5.55B | $2.38B | $1.30B | $535.1M | $1.58B | |
| Enterprise value | $5.43B | $2.29B | $1.12B | $413.0M | $1.47B | |
| EV / Sales | 118.10x | 5.27x | 18.60x | 15.54x | 53.60x | |
| EV / Op. cash flow | 94.23x | 12.44x | -15.89x | -3.82x | -13.60x | |
| EV / Free cash flow | 96.90x | 12.53x | -15.75x | -3.79x | -13.46x | |
| EV / EBITDA | -42.43x | 8.17x | -14.75x | -3.33x | -11.94x | |
| Net debt / EBITDA | 0.92x | -0.31x | 2.45x | 0.98x | 0.96x | |
| Current ratio | 12.71x | 12.48x | 16.71x | 7.80x | 7.74x | |
| Income quality | -0.44x | 0.67x | 0.89x | 0.85x | 0.86x | |
| Graham number | — | $33 | — | — | — | |
| Graham net-net | $8 | $8 | $6 | $4 | $6 | |
| Tax burden | 100.6% | 98.5% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $532.1M | $544.2M | $334.3M | $211.9M | $296.7M | |
| Invested capital | $543.8M | $556.9M | $336.5M | $216.5M | $303.5M | |
| Return on assets | -19.4% | 37.0% | -22.1% | -51.4% | -36.1% | |
| Operating ROA | -22.4% | 45.9% | -30.9% | -44.1% | -37.4% | |
| Return on tangible assets | -19.4% | 37.0% | -22.1% | -51.4% | -36.1% | |
| Return on equity | -21.2% | 40.8% | -23.5% | -59.1% | -41.8% | |
| Return on invested capital | -25.2% | 35.7% | -27.7% | -59.9% | -41.1% | |
| Return on capital employed | -25.3% | 36.3% | -27.8% | -60.6% | -41.4% | |
| Earnings yield | -2.3% | 11.6% | -6.1% | -23.8% | -7.9% | |
| Free cash flow yield | 1.0% | 7.7% | -5.4% | -20.4% | -6.9% | |
| Capex / Op. cash flow | 2.8% | 0.7% | -0.9% | -0.7% | -1.0% | |
| Capex / Depreciation | 124.2% | 46.8% | 18.4% | 23.6% | 39.7% | |
| Capex / Sales | 3.5% | 0.3% | 1.0% | 3.0% | 4.0% | |
| SG&A / Sales | 97.5% | 10.0% | 55.8% | 119.4% | 99.4% | |
| R&D / Sales | 346.2% | 31.8% | 200.3% | 474.8% | 460.6% | |
| Stock comp / Sales | 99.9% | 8.6% | 48.8% | 91.0% | 59.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 36d | 142d | 63d | 1d | 71d | |
| Days payables outstanding | 1591d | 0d | 0d | 0d | 0d | |
| Operating cycle | 36d | 142d | 63d | 1d | 71d | |
| Cash conversion cycle | -1555d | 142d | 63d | 1d | 71d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+133.6%EV / Sales ▲+2140.3%EV / EBITDA ▼-619.2%EV / Op. cash flow ▲+81.795Earnings yield ▼-0.139
Profitability
Return on equity ▼-0.619Return on assets ▼-0.564Return on invested capital ▼-0.609Return on capital employed ▼-0.616Operating ROA ▼-0.682Income quality ▼-1.112Tax burden ▲+0.022
Efficiency
Days sales outstanding ▼-105.899Days payables outstanding n/aOperating cycle ▼-105.899Cash conversion cycle ▼-1696.703Capex / Sales ▲+0.031R&D / Sales ▲+3.144
Balance-sheet strength
Current ratio ▲+0.228Net debt / EBITDA ▲+1.230Working capital ▼-12110000.000Invested capital ▼-13028000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+250.5%EV / Sales ▲+120.3%EV / EBITDA ▼-255.2%EV / Op. cash flow ▲+107.826Earnings yield ▲+0.056
Profitability
Return on equity ▲+0.207Return on assets ▲+0.167Return on invested capital ▲+0.159Return on capital employed ▲+0.161Operating ROA ▲+0.151Income quality ▼-1.302Tax burden ▲+0.006
Efficiency
Days sales outstanding ▼-35.491Days payables outstanding n/aOperating cycle ▼-35.491Cash conversion cycle ▼-1626.295Capex / Sales ▼-0.006R&D / Sales ▼-1.144
Balance-sheet strength
Current ratio ▲+4.969Net debt / EBITDA ▼-0.038Working capital ▲+235413000.000Invested capital ▲+240368000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-09 Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-08 Protagonist Therapeutics Announces $300 Million Share Repurchase Program NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company''s collaboration arrangements with Takeda related to MIMRYLOTM (rusfertide) and with Johnson & Johnson related to ICOTYDETM (icotrokinra).
- 2026-09-02 Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
- 2026-08-31 Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
- 2026-08-31 Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.
- 2026-08-31 Johnson & Johnson Owns Stakes in 15 Stocks. Here''s the Best of the Bunch. J&J''s portfolio primarily includes small biotech and medtech companies. Its largest investment is in the company in its portfolio with the largest market cap.
- 2026-08-28 Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden, and Improve Fatigue Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Response During Weeks 20-32 FDA Approval Triggers $275M in Milestones, 14%-29% Royalties, with Up to an Additional $875M in Potential Future Milestones Investor call to be held Monday, August 31st at 8:30 am ET NEWARK, CA / ACCESS Newswire / August 28, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Takeda received U.S. Food and Drug Administration (FDA) approval for MIMRYLO (rusfertide), a subcutaneously delivered first-in-class hepcidin mimetic peptide for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is the first and only hepcidin mimetic approved for polycythemia vera (PV), a blood cancer characterized by excessive production of red blood cells.
- 2026-08-28 Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,000 shares of the company''s stock, valued at approximately $1,961,000. Several other hedge funds have also made changes to
- 2026-08-18 Protagonist Therapeutics Reports Granting of Inducement Awards NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
- 2026-08-13 Which Small-Cap ETF Is the Better Buy: iShares'' Growth-Focused IWO or Invesco''s Revenue-Weighted RWJ? Small-cap stocks are surging, but how you own them matters more than most investors realize.